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Abstract  
 
Purpose: This study was conducted to identify the maximum-tolerated dose (MTD) of 
fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical 
radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and 
safety data.  
Methods: Patients with unresectable pancreatic cancer confined to the pancreatic region 
were treated with FDR-gem (300-400mg/m2, 5mg/m2/min) on days 1, 8, 22, 29 and 
60mg/m2 of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 
Gy/day, 28fractions) was delivered concurrently. 
Results: Twenty-five patients were enrolled; all were evaluable for toxicity assessment. 
In phase I, eight patients were treated in sequential cohorts of three to five patients per 
dose level. The MTD was reached at level 2, and dose-limiting toxicities were 
neutropenia and thrombocytopenia. The recommended doses were 300mg/m2 of 
gemcitabine and 60mg/m2 of S-1 daily. The overall response rate was 25% and disease 
control rate (partial response plus stable disease) was 92%. The progression-free 
survival was 11.0 months. The median overall survival and 1-year survival rate were 
16.0 months and 73%, respectively. 
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Conclusion: The combination of FDR-gem and S-1 with radiation is a feasible regimen 
that shows favorable antitumor activity with an acceptable safety profile in patients with 
LAPC. 
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Introduction 
 
Pancreatic cancer (PC) is one of the most fatal malignancies worldwide [1]. 
Despite recent improvements in diagnostic techniques, PC is diagnosed at an advanced 
stage in most patients. Among these patients, roughly one-third is diagnosed with 
locally advanced disease [2]. The combination of radiotherapy (RT) and infusional 5FU 
has been considered by many as the standard of care. The pivotal trials have shown a 
survival benefit of chemoradiotherapy (CRT) relative to RT or chemotherapy alone [3]. 
A meta-analysis has also confirmed the significant survival advantage of CRT [4]. 
However, overall survival (OS) of CRT with 5FU is approximately 10 months, 
indicating that the prognosis remains poor. 
 Recently, gemcitabine has been used in some studies because of its systemic 
activity in pancreatic cancer and potent radiosensitizing properties. A number of phase I 
– II trials have combined gemcitabine with RT [5-9]. A phase III trial showed improved 
overall survival in patients with locally advanced pancreatic cancer (LAPC) treated with 
gemcitabine plus radiotherapy compared to gemcitabine alone [10]. In addition, 
gemcitabine administration via infusion at a fixed dose rate of 10mg/m2/min 
(FDR-gem) has been found to increase accumulation of 2’,2’-difluorodeoxycytidine 
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5’-triphosphate (dFdCTP), an active gemcitabine metabolite, compared with 
gemcitabine at a standard dose rate infusion over a period of 30 min. Several studies 
have reported that FDR-gem would be a more effective radiation sensitizer than 
standard injection of gemcitabine based on the higher levels of dFdCTP [11,12]. 
 S-1 is an oral fluoropyrimidine derivative that is designed to improve the 
antitumor activity of 5FU while reducing gastrointestinal toxicity. In S-1, tegafur is 
combined with two 5FU modulators, 5-chloro-2,4-dihydroxypyridine (gimeracil) and 
potassium oxonate (oteracil) in a 1:0.4:1 molar concentration ratio. Gimeracil in S-1 
also acts as a radiosensitizer, and preclinical and clinical studies have demonstrated the 
radiosensitizing potency of S-1 [13]. S-1 has been combined with RT for LAPC in 
several trials [14-16]. In a phase III trial on patients with advanced disease, the 
combination chemotherapy with S-1 and gemcitabine has also shown a higher response 
rate and more favorable progression-free survival (PFS) than monotherapy with S-1 or 
gemcitabine [17]. 
Given the synergy of gemcitabine and S-1, and their respective 
radiosensitization effects, we conducted this phase I/II study to determine the maximum 
tolerated dose (MTD) of FDR-gem combined with S-1 and radical RT and to evaluate 
the toxicity and efficacy in patients with LAPC. 
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Materials and methods 
 
Eligibility 
 
Patients diagnosed with LAPC by histopathological or cytological confirmation 
were enrolled to this study. Eligibility criteria were age ≥ 20 years; Eastern Cooperative 
Oncology Group (ECOG) performance status ≤ 2; no evidence of distant metastasis; 
adequate oral intake; no earlier treatment for pancreatic cancer; adequate hematological 
function (hemoglobin ≥ 10 g/dl, leucocytes ≥ 3,000/mm3, platelets ≥ 100,000/mm3); 
adequate hepatic function (serum total bilirubin ≤ 2.0 mg/dl and serum transaminases 
(aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) ≤ 2.5 times 
upper normal limit (UNL); adequate renal function (serum creatinine ≤ 1.0 mg/dl); 
written informed consent. The exclusion criteria were watery diarrhea; pleural effusion 
or ascites; active infection; active gastroduodenal ulcer; severe complications such as 
heart disease or renal disease; mental disorder; history of drug hypersensitivity; active 
concomitant malignancy; pregnant and lactating females. Multi-detector row computed 
tomography (CT) of the abdomen and chest X-ray were performed for pretreatment 
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staging in order to assess the local extension of the tumor and exclude the presence of 
distant metastasis. The CT-based criteria for tumor nonresectability included tumor 
encasement of the celiac trunk, superior mesenteric artery or bilateral invasion of the 
portal vein. All patients with obstructive jaundice underwent endoscopic retrograde 
biliary drainage before treatment. This study was approved by the institutional review 
boards of the Tokushima University Hospital and Hokkaido Cancer Center and 
conducted in accordance with the Declaration of Helsinki Principles.  
 
Treatment schedule 
 
Figure 1 shows a general schema of the trial. S-1 was administered orally to all 
patients at a dose of 60mg/m2/day on days 1 to 14 and days 22 to 35. Gemcitabine was 
administered by fixed-dose-rate (FDR) intravenous infusion of 5mg/m2/min on days 1, 
8, 22, and 29. The S-1 dosage was set according to the protocol of the previous study of 
S-1 and gemcitabine [17]. Gemcitabine doses were planned to be escalated to 300, 400, 
or 500mg/m2 in subsequent cohorts. Radiotherapy was initiated on day 1 of the study 
using a 10-MV photon beam by a linear accelerator (PRIMUS High-Energy; Toshiba 
Medical Systems Co., Tochigi, Japan) with a four-field technique with each patient in 
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the supine position. A fractional daily dose of 1.8 Gy (5 days/week) at an isocenter, up 
to a total dose of 50.4 Gy, was prescribed. Treatment planning was performed using a 
CT simulator (Asteion, Toshiba Medical Systems Co., Tokyo, Japan) for all patients. CT 
scan was performed with the total breathing phase scan (slow scan) in the free-breathing 
state. CT images were reconstructed with a 2 mm slice thickness. Gross tumor volume 
(GTV) was defined as the primary tumor and involved lymph nodes visible on CT 
images. The clinical target volume (CTV) encompassed the GTV with 0.5 cm isotropic 
margin and the planning target volume was defined as CTV with an isotropic margin of 
0.8 cm for daily patient set-up variation. All dose distributions were computed with the 
Convolution Algorithm implemented in the Xio planning system (CMS Inc., MO, USA). 
No prophylactic nodal irradiation was performed. 
 
Study design 
 
This study was an open-label, multi-center, single-arm phase I/II study 
performed in two steps. For the dose-escalation phase (step 1), the primary endpoint 
was to establish the recommended phase II dose. At least three patients were enrolled at 
each dosage level. If dose limiting toxicity (DLT) was observed in one of the initial 
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three patients, up to three additional patients were enrolled at the same dose level. The 
highest dosage level at which more than two DLT cases occurred was considered the 
MTD. The recommended dose (RD) for the phase II part was defined as the dose level 
one level below the MTD. DLT was defined as grade 4 neutropenia continuing for more 
than 3 days or febrile neutropenia; grade 4 thrombocytopenia; grade 3 or 4 
non-hematological toxicity; any toxicity that necessitated a treatment delay of more than 
15 days. Toxicity was evaluated according to the Common Terminology Criteria for 
Adverse Events (CTCAE) version 3.0. In step 2, the effect of this combination therapy 
on the objective tumor response was evaluated. Tumor response was evaluated at the 
completion of CRT and every 8 weeks thereafter until tumor progression, according to 
Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0 [18]. The severity 
of adverse events, PFS and OS were investigated as secondary objectives. 
 
Results 
 
Patient characteristics 
 
Twenty-five patients were enrolled in this study between September 2008 and 
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February 2013. In phase I of the study, eight patients were treated in sequential cohorts 
at each dose level. After the MTD was defined, 17 additional patients were enrolled to 
confirm the suitability of this RD in phase II of this study. The characteristics of the 
patients are listed in Table 1. Patients had a median age of 68 years (range: 47-81 years). 
ECOG performance status was 0 in 12 patients (48%), 1 in 12 patients (48%), and 2 in 1 
patient (4%). The median maximum tumor size was 42 mm (range: 24-86 mm). The 
causes of the unresectable pancreatic cancers were invasion of the celiac trunk in nine 
patients, invasion of the superior mesenteric artery in six patients, invasion of both 
regions in five patients and invasion of the bilateral portal vein in five patients. 
 
DLTs and RD level 
 
Eight patients were enrolled in phase I of the study and were administered two 
dose levels of gemcitabine combined with 60 mg/m2/day of S-1 and concurrent 
radiotherapy (50.4Gy). At the starting dose of gemcitabine (300 mg/m2), no DLT was 
observed in the three patients. At the dose level 2 of gemcitabine (400 mg/m2), one of 
the first three patients had grade 4 thrombocytopenia, thus an additional three patients 
would have been recruited for the same level. However, the first two of the additional 
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patients experienced DLTs. One of these patients developed grade 4 neutropenia 
continuing for more than 3 days, and the other patient required suspension of treatment 
for more than 15 days due to continuing grade 3 thrombocytopenia. Therefore, this dose 
level was identified as the MTD for this study. We concluded that dose level 1 should be 
considered as the RD for further study. 
 
Toxicity 
 
All 25 patients were evaluated for toxicity. Table 2 summarizes the 
treatment-related clinical adverse events in the patients treated at each dose level 
throughout the treatment period. Major treatment toxicities included myelosuppression. 
Grade 3/4 neutropenia was recorded in 12 of 25 patients (48%). Of the 20 patients 
receiving the RD, eight patients (40%) experienced grade 3/4 neutropenia. Grade 3/4 
thrombocytopenia was observed in five of 25 patients (20%), with three patients (15%) 
presenting with grade 3/4 thrombocytopenia at RD. Grade 1/2 anemia was detected in 
14 patients (54%) with none of them experiencing grade 3/4 toxicity. 
Non-hematological adverse events were manageable. Acute grade 3 or higher 
non-hematological toxicities experienced during the protocol were observed in only 
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12% of the patients and were mild. As a late toxicity, duodenal ulcer was observed 4 
months after treatment in one patient at the RD level. In the phase II part, one patient 
died from septic shock. This patient experienced high fever and abdominal pain 35 days 
after starting chemoradiotherapy. Klebsiella pneumonia was detected in a blood culture, 
but a CT scan showed no specific change. Although antibiotics were administered, the 
patient did not improve. A definitive cause of sepsis could not be determined since 
autopsy was denied. Other treatment-associated symptoms were infrequent or 
negligible. 
 
Efficacy 
Twenty-four patients were available for response assessment, including eight in 
the phase I part and 16 in the phase II part. Five patients achieved a partial response and 
one patient experienced complete response, giving an overall response rate of 25%. 
Nearly all of the remaining patients experienced stable disease as their best response to 
therapy, and only two patients had progressive disease. The overall disease control rate 
was 92% (22/24). At the time of this report, the progression-free survival (PFS) and the 
median overall survival time (MST) were 11.0 months and 16.0 months, respectively 
(Figure 2), and the 1- and 2-year overall survival rates were 73% and 20%, respectively. 
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We compared the patients with arterial-involved tumor (n = 20) with the patients with 
portal-involved tumor (n = 5). However, there is no significant difference between the 
PFS and OS of the two groups. 
 
Discussion 
 
In this trial we established that combination therapy with FDR-gem and S-1 
can be administered safely with concurrent radical RT. The dose of 300 mg/m2 of 
FDR-gem and 60 mg/m2/day of S-1 was determined to be the RD. The regimen was 
overall well tolerated, and the toxicity profile concurs with chemoradiotherapy studies 
using either agent alone [16,10]. The DLT associated with this regimen was 
hematological toxicity, consisting of neutropenia and thrombocytopenia. However, the 
overall toxicity profile in our study was almost identical to those of previous 
gemcitabine-based chemoradiotherapy regimens [5-10]. In the randomized trial which 
compared gemcitabine plus RT and gemcitabine monotherapy, the most frequently 
reported grade 3 and 4 toxicities of gemcitabine plus RT were neutropenia (38%) and GI 
toxicities (nausea: 28% and anorexia: 17%) [10], which were similar to those of the 
present study.  
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Concurrent radiotherapy with S-1 or gemcitabine, respectively, produced very 
favorable results, with mild toxicities, in patient with LAPC [5-10,14-16]. Moreover, 
the combination chemotherapy with gemcitabine and S-1 reportedly has higher 
anticancer activity (objective response rate 29.3%) compared with either treatment 
alone and a favorable median PFS (5.7 months) in patients with advanced disease [17]. 
Although the OS did not differ significantly from that in gemcitabine monotherapy, the 
gemcitabine and S-1 combination therapy showed a favorable hazard ratio for OS in 
patients with LAPC in the subgroup analyses of the phase III trial. Our data suggested 
that chemoradiotherapy using gemcitabine and S-1 concurrently with radiation could be 
a better choice for LAPC. A previous study used combination therapy with gemcitabine, 
S-1, and concurrent radiation as neoadjuvant therapy in patient with resectable PC [19]. 
It concluded that this combination therapy was feasible for patients with resectable PC, 
and 90% (19/21) of enrolled patients successfully underwent surgical resection without 
any severe postoperative complications. However, applying this combination CRT to 
unresectable LAPC has not yet been reported. Moreover, we utilized FDR-gem with S-1 
and radical RT in the present study because several studies have reported that FDR-gem 
would be a more effective radiation sensitizer than bolus injection of gemcitabine based 
on the higher levels of 2’,2’-difluorodeoxycytidine 5’-triphosphate (dFdCTP), an active 
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gemcitabine metabolite [11,12]. 
Our study has demonstrated an overall response rate of 25%, 11.0 months of 
PFS, and 16.0 months of OS. The response rates of previously reported CRT regimens 
with gemcitabine or S-1 alone have ranged from 12% to 41%, and the median PFS have 
ranged from 4.4 to 9.7 months. The present concurrent CRT appears to have a favorable 
treatment efficacy in LAPC as compared to those in the previous reports. In LAPC 
patients receiving chemoradiotherapy it is important to enhance local control while 
simultaneously reduce the risk for distant metastases. In the present trial, the intensive 
combination chemotherapy with FDR-gem plus S-1 and standard-dose radiotherapy 
(50.4 Gy/28 fractions) was easy to administer and had a tolerable toxicity profile. 
Therefore, this regimen might have the dual benefit of counteracting systemic tumor 
spread as well as acting as a potent radiosensitizer for local control. 
In conclusion, this phase I/II study has demonstrated the tolerability to 
combined chemotherapy with FDR-gem and S-1 with radical RT (50.4 Gy) and has 
shown evidence of antitumor activity. 
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Table. 1: Patient charactaristics 
 
Caractaristics 
No. of 
patient 
Gender 
 
    Men 11 
    Women 14 
Age (years) 
 
    Median (range) 68  〔47-81〕 
ECOG performance status 
 
0 12 
1 12 
2 1 
Tumor location 
 
    Head 11 
    Body/Tail 14 
Involved vessels 
 
    Celiac trank 9 
    Superior mesenteric artery 6 
    Both of above 5 
    Portal vein 5 
Tumor size,mm 
 
    Median(range) 42  〔24-86〕 
UICC-TNM 
 
     ⅡA 3 
     ⅡB 2 
     Ⅲ  20 
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Fig.1: Treatment schedule 
Total 50.4Gy (1.8Gy/day, 5times/week, 28 fractions) of radiation was administered 
along with concurrent intravenous infusion of gemcitabine on days 1,8, 22, and 29 
and S-1 orally on days 1-5, 8-12, 22-26, and 29-33.
Fig.2: Kaplan-Meier curves of progression free survival (A) and overall survival (B) for 
25 patients. 
Day1                8              15             22              29              36           
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